Abstract: The present invention discloses the use of RNA inhibitory molecules, particularly siRNA molecules silencing the expression of Voltage-Dependent Ion Chanel-1 (VDAC1) for the induction of cancer stem cell differentiation and reduction of TAMs abundance and tumor angiogenesis, thereby preventing tumor invention and recurrence.

Abstract: The present disclosure is directed to methods of genetically detecting or generating a peanut line that is resistant to peanut smut infection. The disclosure also relates to cultivation of smut resistant peanut lines and the cessation or prevention of peanut smut in a given geographic area.

Abstract: Modified cells comprising a transmembrane polypeptide comprising at least one extracellular target receptor-binding domain, a transmembrane domain and an intracellular domain, wherein said intracellular domain is not capable of transducing any signal are provided. Methods of inducing or inhibiting signaling by a target receptor in a target cell comprising contacting the target cell with a modified cell of the invention are also provided.

Abstract: The present disclosure provides for and relates to novel fusion proteins and polypeptides expressed by breast cancer and other cancer cells, and to compositions, materials and methods for detecting, characterizing and treating said breast and other cancers. In one embodiment, the fusion polypeptides are read-through fusion transcripts.

Abstract: Modified cells comprising a transmembrane polypeptide comprising at least one extracellular target receptor-binding domain, a transmembrane domain and an intracellular domain, wherein the intracellular domain is not capable of transducing any signal are provided. Methods of inducing or inhibiting signaling by a target receptor in a target cell comprising contacting the target cell with a modified cell of the invention are also provided.

Abstract: The present disclosure is directed to methods for verifying the genetic makeup of a target product, for example, products in a supply chain. The methods relate to the use of genomics for confirming or verifying the genetic makeup of the target product. The methods also relate to the use of genomics for detecting the presence or absence of one or more gene variants associated with a specific phenotypic quality or characteristic in the target product. The presently disclosed method verifies and/or detects certain genetic markers of the target product using whole genome sequencing (WGS) to access the entire genome.

Abstract: The present disclosure provides CpG oligodeoxynucleotides (ODNs) as immunogenic molecules, and their use in methods of initiating or promoting innate or adaptive immunity in fish or increasing an immune response against an antigen in fish.

Abstract: Mutant M-CSF protein, comprising ?v?3 integrin binding motif and pharmaceutical compositions comprising same, are provided. Further, use of the composition for the treatment and or prevention of diseases associated with increased bone resorption are provided.

Abstract: The present invention relates to compositions and methods for treating cancer, particularly to agents that inhibit the expression and/or activity of the protein second mitochondria-derived activator of caspase/direct inhibitor of apoptosis-binding protein with low pI (SMAC/Diablo). The inhibiting agents include RNA interference molecules silencing the expression of SMAC/Diablo and peptides modulating its interactions within the cell nucleus and mitochondria. The methods and agents of the present invention are useful in treating cancers associated with overexpression of SMAC/Diablo.

Abstract: Peptides derived from NKp44 protein, chimeric peptides, nucleotides encoding same and pharmaceutical compositions comprising same, are provided. Further, methods of extending the biological half-life of a protein of interest are provided.

Abstract: A method of reducing the abundance of a non-target micro-RNA (miRNA) that is part of a group of miRNAs is provided, including: (a) annealing a complementary region of a blocking nucleic acid to a binding site at a first end of the unwanted miRNA, ligating an adenylated nucleic acid adapter to the group of miRNAs, and performing RT-PCR on group of miRNAs. Kits and compounds for use with the method are also provided.

Abstract: The presently disclosed subject matter provides compositions and methods comprising isolated antibodies that can recognize human prostate-specific membrane antigen (PSMA). The presently disclosed antibodies can be used to for imaging and therapy of PSMA-expressing cancers, such as prostate cancer, in a subject.

Abstract: The present invention provides a monoclonal antibody or an antigen-binding portion thereof having increased binding affinity to cytoplasmic PCNA and blocks its interaction with NKp44. The present invention further provides use of the antibody or an antigen-binding portion thereof in the treatment of diseases associated with elevated expression of NKp44, such as cancer.

Abstract: A method of altering the composition of the microbiome of an adult ruminant is disclosed. The method comprises administering to the ruminant when it is the newborn stage of life, a composition which alters the amount of bacteria of the Akkermansia genus in the microbiome of the newborn ruminant, thereby altering the composition of the microbiome of the adult ruminant.

Abstract: The present invention relates to peptides comprising analogues of VDAC1-derived peptides having improved pharmacokinetic characteristics compared to the native parent peptides, which are effective in impairing cell energy production, in inducing apoptosis and cell death, particularly of cancerous cells, in eliminating cancer stem cells and in reducing symptoms associated with fat accumulation in liver cells particularly with nonalcoholic fatty liver disease (NAFLD) and symptoms associated thereto.

Abstract: The invention relates to a plasmid, a DNA assembly method and its application recombinant strain. The plasmid has single adjacent Type IIP and Type IIS RE recognition sites. The plasmid combines the properties of Type IIP and Type IIS REs to achieve recursive cycling, SCAR-free and repeat sequence assembly.

Abstract: A method of selecting a ruminating animal having a desirable, hereditable trait is disclosed. The method comprises analyzing in the microbiome of the animal for an amount of a hereditable microorganism which is associated with the hereditable trait, wherein the amount of the hereditable microorganism is indicative as to whether the animal has a desirable hereditable trait.

Abstract: The present disclosure provides for and relates to the identification of novel biomarkers for diagnosis and prognosis of prostate cancer or the biochemical reoccurrence of prostate cancer. The biomarkers of the invention show altered methylation levels of certain CpG loci relative to normal prostate tissue, as set forth.

Abstract: The present invention relates to compositions and methods for treating cancer, particularly to agents that inhibit the expression and/or activity of the protein second mitochondria-derived activator of caspase/direct inhibitor of apoptosis-binding protein with low pI (SMAC/Diablo). The inhibiting agents include RNA interference molecules silencing the expression of SMAC/Diablo and peptides modulating its interactions within the cell nucleus and mitochondria. The methods and agents of the present invention are useful in treating cancers associated with overexpression of SMAC/Diablo.

Abstract: Provided herein piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting VDAC oligomerization, apoptosis and mitochondria dysfunction. Also provided methods of treatment of diseases associated with said processes, e.g. Alzheimer's and Parkinson's diseases.